Results 221 to 230 of about 115,960 (309)

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

Clinical Implications of Immune Dysfunction in Chronic Lymphocytic Leukemia. [PDF]

Cancers (Basel)
Juárez-Salcedo LM, Loscertales J.
europepmc   +1 more source

Leukemia cutis (chronic lymphocytic leukemia-low grade B cell)

Dermatology Online Journal, 2002
openaire   +4 more sources

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. [PDF]

Cancer Med
Liao PW, Ko BS, Su YC, Chao WT, Teng CJ.
europepmc   +1 more source

Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape

The FEBS Journal, EarlyView.
The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto, Naike Casagrande, Emanuele Di Siena, Greta Carobolante, Lucrezia Camicia, Giorgia Schinello, Samanta Muzzin, Enrica Timis, Paola Spessotto, Maurizio Mongiat   +9 more
wiley   +1 more source

Hematolymphoid neoplasms involving the breast: A single institution clinicopathologic study of 59 patients. [PDF]

Ann Hematol
Vickery J, Peerenboom R, Siddiqui F, Joy JA, Prabu SS, Arber DA, Gurbuxani S, Biernacka A, Venkataraman G.   +8 more
europepmc   +1 more source

Treatment of advanced cutaneous squamous cell carcinoma with cemiplimab in elderly multimorbid patients – a case series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Patryk Porebski, Katharina Amschler, Michael P. Schön, Kai‐Martin Thoms   +3 more
wiley   +1 more source

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

Unusual Nasopharyngeal Localization of Chronic Lymphocytic Leukemia: A Case Report. [PDF]

Cureus
Fadi M, Anajar S, Chahdi H, Lahlou FA, Bouanani N.   +4 more
europepmc   +1 more source